Data as of 1:37pm ET
| +0.05 / +0.08%|
The 14 analysts offering 12-month price forecasts for Cubist Pharmaceuticals Inc have a median target of 83.50, with a high estimate of 97.00 and a low estimate of 64.00. The median estimate represents a +35.88% increase from the last price of 61.45.
The current consensus among 17 polled investment analysts is to Buy stock in Cubist Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.